

May 31, 2016



VolitionRx to Present at Two Upcoming Conferences in June

Company to Provide Updates on NuQ® Blood Test Platform at Marcum MicroCap and LD Micro Conferences

NAMUR, Belgium, May 31, 2016 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX) today announced that the Company is scheduled to present at the Marcum MicroCap Conference being held June 1-2 in New York, NY and at the LD Micro Invitational conference, being held June 7-9 in Los Angeles, CA.

During the presentations, the Company will discuss recent clinical, regulatory and operational milestones and outlook for the future, including the planned European commercialization of the Company's NuQ® blood-based test platform, first for colorectal cancer, and the initiation of additional studies in pancreatic, prostate and lung cancers as well as other indications.

Details of the presentations are as follows:

Conference: 2016 Marcum MicroCap Conference
Date: Wednesday, June 1, 2016
Time: 02:00 p.m. EDT
Location: Grand Hyatt New York, Broadway Room

Conference: LD Micro Invitational
Date: Wednesday, June 8, 2016
Time: 9:00 a.m. PDT
Location: Luxe Sunset Bel Air, Track 4

Persons attending either conference who are interested in meeting with management may request a meeting via the respective conference's portal or by contacting Joseph Green or Lee Roth at 646-536-7013 / 7012 or jgreen@theruthgroup.com / lroth@theruthgroup.com.

About VolitionRx

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (<http://www.volitionrx.com>) or connect with us via [Twitter](#), [LinkedIn](#),

[Facebook](#) or [YouTube](#).

Media Contacts

Louise Day, VolitionRx

L.day@volitionrx.com

+44 (0) 7557 774620

Kirsten Thomas, The Ruth Group

kthomas@theruthgroup.com

+1 (508) 280-6592

Investor Contacts

Scott Powell, VolitionRx

S.Powell@volitionrx.com

+1 (646) 650-1351

Lee Roth, The Ruth Group

lroth@theruthgroup.com

+1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company's bodily-fluid-based diagnostic tests as well as the Company's ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics[®], NuQ[®] and HyperGenomics[®] and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-to-present-at-two-upcoming-conferences-in-june-300276855.html>

SOURCE VolitionRx Ltd